Erik Hertervig
Overview
Explore the profile of Erik Hertervig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergqvist V, Gedeon P, Hertervig E, Marsal J
Gastrointest Endosc
. 2025 Mar;
101(3):695-696.
PMID: 40024648
No abstract available.
2.
Ersboll A, Huang Z, Hill D, Hede S, Andersen V, Bolin K, et al.
Drug Saf
. 2025 Feb;
PMID: 39913070
Background: When golimumab (GLM) was approved for the treatment of moderate to severe ulcerative colitis (UC) in 2013, a post-authorization safety study was conducted. Objective: Our objective was to examine...
3.
Visuri I, Eriksson C, Karlqvist S, Lykiardopoulos B, Karlen P, Grip O, et al.
Therap Adv Gastroenterol
. 2023 Jun;
16:17562848231174953.
PMID: 37274297
Background: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. Objective: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). Design: A...
4.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, et al.
Lancet Gastroenterol Hepatol
. 2023 Jan;
8(3):215-227.
PMID: 36640794
Background: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for...
5.
Eriksson C, Visuri I, Vigren L, Nilsson L, Karnell A, Hjortswang H, et al.
Scand J Gastroenterol
. 2021 Aug;
56(11):1304-1311.
PMID: 34415803
Objectives: Clinical trials demonstrated that golimumab is effective in anti-TNF naïve patients with ulcerative colitis. We aimed to assess the clinical effectiveness of golimumab in a real-world setting. Materials And...
6.
Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlen P, Grip O, et al.
Therap Adv Gastroenterol
. 2021 Jul;
14:17562848211023386.
PMID: 34276808
Background: Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD). Methods: This study was...
7.
Ungaro R, Yzet C, Bossuyt P, Baert F, Vanasek T, DHaens G, et al.
Gastroenterology
. 2020 Apr;
159(1):139-147.
PMID: 32224129
Background & Aims: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). Methods: We collected follow-up data from 122 patients (mean age, 31.2 ±...
8.
Angelison L, Almer S, Davidsdottir L, Hammarlund P, Lindgren S, Hindorf U, et al.
Scand J Gastroenterol
. 2020 Jan;
55(2):154-162.
PMID: 31961234
Randomized controlled trials have shown the effectiveness of Adalimumab in ulcerative colitis. However, real-life data is scarce. We aimed to assess the effectiveness and predictive factors of effectiveness in a...
9.
Bolin K, Hertervig E, Louis E
J Crohns Colitis
. 2019 Mar;
13(10):1323-1333.
PMID: 30893421
Objectives: To examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clinical remission, with a combination of anti-tumour necrosis factor alpha [anti-TNFα] [infliximab] and immunomodulator therapy...
10.
Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, et al.
Therap Adv Gastroenterol
. 2018 Oct;
11:1756284818801244.
PMID: 30344642
Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab...